Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 1.00 |
| ▸ | LHCGR | P22888 | 1/20 | 0.80 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.76 |
| ▸ | RAB9A | P51151 | 1/20 | 0.76 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.75 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.75 |
| ▸ | FAAH2 | Q6GMR7 | 1/20 | 0.75 |
| ▸ | MGLL | Q99685 | 1/20 | 0.75 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL530169 | 1.00 | FAAH (1.00) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089418 | 0.99 | FAAH (0.97) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089399 | 0.93 | FAAH (0.88) | FAAHLHCGRALDH1A1RAB9ATRPA1 | |
| SCHEMBL10089404 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089402 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089406 | 0.90 | FAAH (0.81) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089403 | 0.88 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089425 | 0.88 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089426 | 0.88 | FAAH (0.79) | FAAHTRPA1EPHX2FAAH2MGLL | |
| SCHEMBL10089400 | 0.87 | FAAH (0.84) | FAAHTRPA1EPHX2FAAH2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2026-04-16 | — | — | US | disclosed |
| EP-4665718-A1 | SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF | Apogee Pharmaceuticals, Inc. (CA) | 2025-12-24 | — | — | EP | disclosed |
| US-12421281-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-09-23 | — | — | US | disclosed |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | APOGEE PHARMACEUTICALS, INC. (CA) | 2025-08-05 | — | — | US | disclosed |
| US-20250205175-A1 | Anti-Aging Composition with mTOR inhibitor for Humans and Other Mammals | POSTREL RICHARD (US) | 2025-06-26 | — | — | US | disclosed |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-06-05 | — | — | US | disclosed |
| US-20250152562-A1 | Compositions to Enhance and Extend Quality of Life | POSTREL RICHARD (US) | 2025-05-15 | — | — | US | disclosed |
| WO-2025085674-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS | BACAINN THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12280019-B2 | Anti-aging therapy for humans and other mammals | POSTREL RICHARD (US) | 2025-04-22 | — | — | US | disclosed |
| US-12252556-B2 | Cyclosporine compositions and methods of use | BACAINN BIOTHERAPEUTICS, LTD. (KY) | 2025-03-18 | — | — | US | disclosed |
| WO-2022225839-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | BACAINN THERAPEUTICS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
| EP-3449943-B1 | A PHARMACEUTICAL COMPOSITION FOR IMPROVING OR PREVENTING PROGRESSION OF CHRONIC KIDNEY DISEASE | FRIMLINE PRIVATE LTD (IN) | 2022-08-31 | — | — | EP | disclosed |
| US-20220265646-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | ITÄ-SUOMEN YLIOPISTO (FI) | 2022-08-25 | — | — | US | disclosed |
| US-20220249434-A1 | Reversal of Baldness in Men and Women through Cannabinoid Receptor Activation | POSTREL RICHARD (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220175694-A1 | Anti-Aging Therapy for Canines and Other Domesticated Animals | POSTREL RICHARD (US) | 2022-06-09 | — | — | US | disclosed |
| EP-3996702-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | Itä-Suomen Yliopisto (FI) | 2022-05-18 | — | — | EP | disclosed |
| US-11331300-B2 | Reversing baldness through follicle regeneration | POSTREL RICHARD (US) | 2022-05-17 | — | — | US | disclosed |
| US-11318093-B2 | Dental topical anesthetic gel | PAC-DENT, INC. | 2022-05-03 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| CN-114126617-A | Piezoelectric agonists for preventing or reversing abnormal amyloid deposition | 东芬兰大学 | 2022-03-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12252556-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | FAAH 1629/4885LHCGR 3696/4885ALDH1A1 3535/4885 |
| US-20260103492-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | ABCC1, SLC47A2, ABCB1 | FAAH 2184/4885LHCGR 4015/4885ALDH1A1 3772/4885 |
| US-12421281-B2 | Cyclosporine compositions and methods of use | FPR2, FPR1, FPR3 | FAAH 2000/4885LHCGR 3882/4885ALDH1A1 4140/4885 |
| US-12378231-B2 | Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof | MGLL, PNLIP, LPL | FAAH 12/4885LHCGR 4239/4885ALDH1A1 530/4885 |
| US-20250179121-A1 | CYCLOSPORINE COMPOSITIONS AND METHODS OF USE | FPR2, FPR1, FPR3 | FAAH 1629/4885LHCGR 3696/4885ALDH1A1 3535/4885 |
| US-20220265646-A1 | PIEZO AGONISTS FOR PREVENTING OR REVERTING ABNORMAL AMYLOID DEPOSITION | PIEZO1, STIM2, ADRA1D | FAAH 2921/4885LHCGR 4671/4885ALDH1A1 3352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.